<DOC>
	<DOCNO>NCT01009086</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness ( improvement sign symptom ) safety ustekinumab participant active psoriatic arthritis .</brief_summary>
	<brief_title>A Study Safety Effectiveness Ustekinumab Patients With Psoriatic Arthritis</brief_title>
	<detailed_description>This randomize ( participant assign different treatment base chance ) , double-blind ( neither participant physician know whether drug placebo take , dosage ) , parallel-group ( group participant treat time ) , multicenter ( study conduct multiple site ) study . Approximately , 615 participant participate study . Participants assign one three treatment group : Group I : ustekinumab 45 mg , Group II : ustekinumab 90 mg , Group III : placebo group ( inactive substance ) . Participants receive either 45 mg ustekinumab 90 mg ustekinumab Weeks 0 , 4 , every 12 week Week 88 randomize respective group . Participants placebo group receive placebo Weeks 0 , 4 , 16 , 20 45 mg ustekinumab Weeks 24 28 follow every 12 week dose Week 88 . Participants great equal 5 percentage improvement disease ( tender swollen joint ) eligible early escape . Specifically , early escape Week 16 , participant Group I receive 90 mg ustekinumab , participant Group II dose schedule continue , participant placebo group receive 45 mg ustekinumab . Safety evaluation include assessment adverse event , clinical laboratory test , physical examination . The maximum study duration approximately 108 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have document diagnosis psoriatic arthritis ( PsA ) least 6 month Have diagnosis active PsA time entry study If participant use methotrexate start treatment dose exceed 25 milligram per week least 3 month prior begin study serious toxic side effect attributable methotrexate . Methotrexate route administration dose stable least 4 week prior first administration study agent . If currently use methotrexate , must receive methotrexate least 4 week prior first administration study agent Have inflammatory disease , include limited rheumatoid arthritis , ankylose spondylitis , systemic lupus erythematosus , Lyme disease Have use therapeutic agent target reduce interleukin ( IL ) 12 IL23 , include limited ustekinumab briakinumab ( ABT874 ) Have use biologic agent target reduce tumor necrosis factoralpha , include limited infliximab , etanercept , adalimumab , golimumab Have medical history latent active granulomatous infection Have know malignancy history malignancy ( exception basal cell carcinoma , squamous cell carcinoma situ skin , cervical carcinoma situ treat evidence recurrence , squamous cell carcinoma skin treat evidence recurrence within 5 year begin study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Arthritis , Psoriatic</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>CNTO 1275</keyword>
	<keyword>Stelara</keyword>
	<keyword>Psoriasis</keyword>
</DOC>